AZN · story · 31 October
AstraZeneca · 59 headlines from 40 outlets, on 31 October 2026.
AstraZeneca reported 7% Q3 revenue growth, kept guidance, and launched a $1.5bn savings plan funding a $2bn pipeline investment; shares rose sharply.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Investor's Business Daily is the largest at 10.0, ahead of Reuters (10.0). TradingView is the smallest at 4.8.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Yahoo Finance | 7.6 |
| MarketScreener | 8.1 |
| Yahoo Finance UK | 7.8 |
| Sharecast | 7.5 |
| TradingView | 4.8 |
| BioSpace | 6.3 |
| Investor's Business Daily | 10.0 |
| Reuters | 10.0 |
| Euronews.com | 10.0 |
| Bloomberg | 10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Yahoo Finance | 11 | +7.6 |
| MarketScreener | 4 | +8.1 |
| Yahoo Finance UK | 3 | +7.8 |
| Sharecast | 2 | +7.5 |
| TradingView | 3 | +4.8 |
| BioSpace | 2 | +6.3 |
| Investor's Business Daily | 1 | +10.0 |
| Reuters | 1 | +10.0 |
| Euronews.com | 1 | +10.0 |
| Bloomberg | 1 | +10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Business Weekly | 1 | +10.0 |
| London South East | 1 | +10.0 |
| TradingKey | 1 | +10.0 |
| Proactive Investors UK | 1 | +9.2 |
| City AM | 1 | +9.2 |
| France 24 | 1 | +9.2 |
| Simply Wall St | 1 | +9.2 |
| AOL | 1 | +9.2 |
| Interactive Investor | 1 | +8.3 |
| Proactive financial news | 1 | +8.3 |
| BigGo Finance | 1 | +8.3 |
| Fierce Pharma | 1 | +7.5 |
| GenomeWeb | 1 | +7.5 |
| The Pharma Letter | 1 | +7.5 |
| Evening Standard Business | 1 | +6.7 |
| WSJ | 1 | +6.7 |
| EMJ | 1 | +6.7 |
| Business Live | 1 | +6.7 |
| Quartz | 1 | +6.7 |
| CNBC | 1 | +6.7 |
| ayrshire-today.co.uk | 1 | +6.7 |
| MedWatch | 1 | +6.7 |
| Clinical Trials Arena | 1 | −5.8 |
| Finimize | 1 | +5.8 |
| Barron's | 1 | +5.0 |
| The Times | 1 | +4.2 |
| AskTraders | 1 | +4.2 |
| Fierce Biotech | 1 | −3.3 |
| Endpoints News | 1 | −3.3 |
| STAT | 1 | +2.5 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Shares at multi-month high on chief executive's large pipeline potential claim |
| +10.0 | Sharp share price rise after results |
| +10.0 | Confident chief executive and rising shares |
| +10.0 | Large potential from upcoming trial data, shares near breakout |
| +10.0 | Sharp profit rise and cost savings programme |
| +10.0 | Shares rallied on earnings beat and cancer drug growth |
| +10.0 | Profit lifted by leading cancer medicines |
| +10.0 | Long growth outlook backed by pipeline and approvals |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Earnings call points to strong cancer drug sales growth |
| +10.0 | Earnings beat driven by cancer drug sales |
| +10.0 | Strong share gain despite capped restructuring spend |
| +10.0 | Sales and profit beat forecasts, shares up |
| +10.0 | Shares climbed strongly on the day |
| +9.2 | Record margin viewed as encouraging for next year |
| +9.2 | Shares leap as pipeline investment begins |
| +9.2 | Higher profits and savings plan |
| +9.2 | Investment case strengthened by better-than-expected results |
| +9.2 | Valuation commentary sees upside after strong quarter and pipeline progress |
| +9.2 | Savings target and results ahead of forecasts |
| +9.2 | Bank analyst keeps positive rating, praises pipeline activity |
| +8.3 | Analyst commentary optimistic on potential major drugs |
| +8.3 | Earnings call summary, generally positive tone |
| +8.3 | Brokers view profit beat favourably, shares gain |
| +8.3 | Revenue up and full-year guidance reaffirmed |
| +8.3 | Strong year-to-date beat, guidance unchanged |
| +8.3 | Higher adjusted earnings and revenue, outlook kept |
| +8.3 | Strong drug sales and pipeline value offset by restructuring cost |
| +8.3 | Broker positive recommendation |
| +8.3 | Broker maintains positive rating |
| +7.5 | Savings plan with workforce kept stable |
| +7.5 | Multi-year efficiency programme aimed at funding late-stage development |
| +7.5 | Revenue growth from cancer offsets decline of one drug |
| +6.7 | Overhaul aimed at lowering annual costs |
| +6.7 | Savings programme to finance drug development |
| +6.7 | Annual cost savings planned to support pipeline |
| +6.7 | Savings to be redirected into growth |
| +6.7 | Investment into drug pipeline begins |
| +6.7 | Savings plan announced alongside quarterly results |
| +6.7 | Finance chief discusses results and pipeline outlook |
| +6.7 | Solid quarterly figures |
| +6.7 | Overhaul aimed at lowering annual costs |
| +6.7 | Savings freed up for new medicines |
| +6.7 | Full-year profit outlook maintained |
| −5.8 | Late-stage trial halted due to disappointing expected efficacy |
| +5.8 | Official nine-month and quarterly results release |
| +5.8 | Reorganisation intended to fund pipeline |
| +5.0 | Revenue rise noted at market open |
| +5.0 | Key metrics compared with analyst expectations |
| +5.0 | Ambitious growth target but share price had stalled |
| +5.0 | Finance chief interview on AI, results and restructuring |
| +4.2 | Restructuring spend announced for drug pipeline |
| +4.2 | Brief roundup of results among several firms |
| +4.2 | Guidance held despite pressure from generics |
| +4.2 | Restructuring will not reduce overall headcount |
| −3.3 | Early-stage prostate cancer programmes dropped |
| −3.3 | Reorganisation may bring research cuts and trials moved abroad |
| +2.5 | Newsletter roundup mentioning its cost cutting |
| +1.7 | Transcript of results call, factual |
| 0.0 | Notice that results call is under way |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.